Publicaciones en las que colabora con Luis Miguel Blanco Colio (18)

2013

  1. HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 33, Núm. 3, pp. 612-620

2011

  1. TWEAKFn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells

    Cardiovascular Research, Vol. 89, Núm. 1, pp. 225-233

2010

  1. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis

    Cardiovascular Research, Vol. 86, Núm. 2, pp. 330-337

2009

  1. Increased CD74 expression in human atherosclerotic plaques: Contribution to inflammatory responses in vascular cells

    Cardiovascular Research, Vol. 83, Núm. 3, pp. 586-594

  2. Leukotriene B4 enhances the activity of nuclear factor-κB pathway through BLT1 and BLT2 receptors in atherosclerosis

    Cardiovascular Research, Vol. 81, Núm. 1, pp. 216-225

  3. The CD163-expressing macrophages recognize and internalize TWEAK. Potential consequences in atherosclerosis

    Atherosclerosis, Vol. 207, Núm. 1, pp. 103-110

2008

  1. LDL induces parathyroid hormone-related protein expression in vascular smooth muscle cells: Modulation by simvastatin

    Atherosclerosis, Vol. 198, Núm. 2, pp. 264-271

  2. Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis

    Kidney International

2007

  1. Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques

    European Journal of Pharmacology, Vol. 562, Núm. 1-2, pp. 119-129

2006

  1. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: Potential implications for plaque stabilization

    Journal of Cardiovascular Pharmacology, Vol. 47, Núm. 1, pp. 60-69

  2. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: Modulation by atorvastatin

    Stroke, Vol. 37, Núm. 8, pp. 2044-2053

  3. Overexpression of COX-2, Prostaglandin E Synthase-1 and Prostaglandin E Receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-κB

    Atherosclerosis, Vol. 187, Núm. 1, pp. 139-149

2005

  1. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month

    Stroke, Vol. 36, Núm. 8, pp. 1796-1800

2004

  1. NF-κB Activation and Fas Ligand Overexpression in Blood and Plaques of Patients with Carotid Atherosclerosis: Potential Implication in Plaque Instability

    Stroke, Vol. 35, Núm. 2, pp. 458-463

2003

  1. Simvastatin reduces NF-κB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet

    Cardiovascular Research, Vol. 57, Núm. 1, pp. 168-177

2002

  1. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells

    Atherosclerosis, Vol. 160, Núm. 1, pp. 49-58

2001

  1. Atorvastatin reduces Fas and Fas ligand expression in a rabbit experimental model of atherosclerosis

    Investigacion Cardiovascular, Vol. 4, Núm. 1, pp. 15-27

  2. Simvastatin reduces inflammation in rabbit atheroma more markdely than dietary lipid lowering

    Investigacion Cardiovascular, Vol. 4, Núm. 1, pp. 28-42